Selective HDAC IIa inhibition was identified as a viable alternative approach to avoid the potential adverse effects of broad spectrum HDAC inhibition in pulmonary arterial hypertension.
MicroRNAs (miRs) 424 and 503 are effective in human and animal models of pulmonary arterial hypertension and may be the basis for effective therapeutics.
OCR5753 is the most potent anti-HIV agent with activity towards wild-type HIV-1. OCR5753 is 10 times more potent than any NNRTI reported to date.
A small-molecule named “antibody-recruiting molecule targeting HIV-1 (analog 3)” (ARM-H-3) targeted for the treatment of HIV (240nM HIV antagonist).
OCR 5557 offers neutralizing monoclonal and rabbit polyclonal antibodies that are not cross-reactive with macrophage migration inhibitory factor (MIF).
Animal-free product that avoids pathogen or immunogenic contamination of animal products.
Neutralizing antibodies to OCR6325 are potential immune therapeutic agents to treat cancers that overexpress a novel soluble target expressed in epithelia.
The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD.